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Background: The noninvasive prenatal diagnosis procedures that are currently used to detect genetic diseases do
not achieve desirable levels of sensitivity and specificity. Recently, fetal methylated DNA biomarkers in maternal
peripheral blood have been explored for the noninvasive prenatal detection of genetic disorders. However, such
efforts have covered only chromosomal aneuploidy, and fetal methylated DNA biomarkers in maternal whole blood
for detecting single-gene diseases remain to be discovered.
Methods: To address this issue, we systematically screened significantly hypermethylated genes in fetal tissues and
compared them with maternal peripheral blood potential in an attempt to detect fetal genes in maternal
peripheral blood. First, the methylated-CpG island recovery assay combined with a CpG island array was performed
for four fetus-toward placental tissues and the corresponding maternal peripheral bloods. Subsequently, direct
bisulfite sequencing and combined bisulfite restriction analysis (COBRA) were carried out to validate the
methylation status of the hypermethylated genes that were identified by the microarray analysis.
Results: Three hundred and ten significantly hypermethylated genes in the placental tissues were detected by
microarray. From the top 15 hypermethylated genes detected by microarray, two were selected for sequencing
validation in placental tissue and chorionic villus samples and four were selected for COBRA validation in four
placental tissues, ten amniotic fluids and five chorionic villus samples. The six selected genes were confirmed to be
hypermethylated in placental tissue and chorionic villus samples, but methylation of the genes could not be
detected in the amniotic fluids.
Conclusions: Of the many hypermethylated genes and methylation sites that were found in the fetal tissues, some
have great potential to be developed into molecular markers for noninvasive prenatal diagnosis of monogenic
disorders. Further clinical studies are warranted to confirm these findings.
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Definitive prenatal diagnosis of genetic diseases usually
requires obtaining fetal genetic material by invasive pro-
cedures such as amniocentesis, chorionic villus sampling
and cordocentesis. These invasive procedures put the
fetus at a small but significant risk and, therefore, are
carried out only when the risk of abnormal pregnancy,
estimated by maternal age, ultrasonography and other
noninvasive methods, outweighs the risk of miscarriage
caused by such procedures [1]. Noninvasive procedures
are also available for prenatal diagnosis. These proce-
dures use maternal periphery blood samples and quan-
tify maternal serum proteins that are surrogate markers
of the underlying genetic abnormality. Such noninvasive
diagnostic procedures do not achieve the desirable levels
of sensitivity and specificity, and they are not definitive
[2]. For these reasons, great efforts have been made in
the last decade to develop fetal molecular biomarkers
for noninvasive prenatal diagnosis.
The discovery of circulating fetal free DNA in the
plasma of pregnant women opened up new doors for
noninvasive prenatal diagnosis [3]. Early studies have
mainly examined gender and polymorphic differences
between the fetus and its mother. Fetal molecular bio-
markers based on differences of this kind can be used
only to detect paternally inherited disease [4,5]. In 2002,
Poon et al.[6] first demonstrated that methylation differ-
ences between fetal DNA and maternal whole blood
DNA could potentially be used as universally applicable
fetal molecular markers for noninvasive prenatal diagno-
sis. Since then, a number of studies have focused on the
identification of differential methylation patterns be-
tween the fetus and the maternal peripheral blood [7,8].
Recently, Papageorgiou et al. [9] used methylated DNA
immunoprecipitation (MeDiP) coupled with high-
resolution tiling oligonucleotide array analysis to identify
more than 2,000 differentially methylated regions (DMR)
between female whole blood and placental DNA on
chromosomes 13, 18, 21, X, and Y. In a subsequent
study, they achieved the noninvasive prenatal detection
of trisomy 21 by determining the fetal-specific DMRs
present in the maternal peripheral blood of normal and
trisomy 21 cases [10]. These studies were targeted to-
wards the noninvasive prenatal detection of chromo-
somal aneuploidy and not towards single-gene genetic
diseases.
In the present study, we systematically searched for
potential methylation biomarkers for the noninvasive
prenatal genetic detection of various inherited diseases,
including single-gene genetic diseases and chromosomal
aneuploidy. First, we used the methylated-CpG island re-
covery assay (MIRA) to capture methylated DNA. Then
we performed a long oligonucleotide microarray analysis
to characterize methylation patterns in the placenta atthe first, second and third trimester of pregnancy. The
microarray contained 60 k 60-mer probes that interro-
gate 4,162 genes distributed on the 23 pairs of chromo-
somes. The MIRA assay is based on the high affinity of
the methyl-CpG-binding domain (MBD) protein which spe-
cifically recognizes methylated CpG dinucleotides [11-13].
Papageorgiou et al. [14-16] used 5-methylcytosine-
specific antibodies to enrich methylated DNA; however,
their method requires single-stranded DNA for recog-
nition. Compared to this approach, the MIRA-based
approach that we have proposed is more specific and




Seven pairs of samples of matched maternal peripheral
blood and fetus-toward placental tissue were obtained
from seven healthy pregnant women. Four of the pairs
were randomly selected for microarray analysis and
combined bisulfite restriction analysis (COBRA); the
three other pairs were used to confirm the bisulfite se-
quencing. Maternal peripheral bloods were collected in
the fasting state before delivery, and placental tissues
were sampled within 30 min of delivery. Five chorionic
villus and ten amniotic fluid samples were collected in
first-trimester and second-trimester pregnancies respect-
ively, to validate the methylation status of the hyper-
methylated genes identified using the microarray. Before
the samples were used in this study, the following dis-
eases were excluded using the retrospective clinical cri-
teria: pre-eclampsia, gestational diabetes, intrauterine
growth restriction, preterm delivery and spontaneous
abortion after detection of a fetal structural or chromo-
somal abnormality. All samples were snap-frozen in li-
quid nitrogen within 6 hrs of collection and stored at
−80°C until the DNA was isolated. The experiments
were approved by the Ethics Committee at the Guang-
dong Women and Children Hospital. Informed written
consent was obtained from all participants.
MIRA microarray analysis of DNA methylation
The MIRA-based microarray analysis was performed as
described previously [17] with minor modifications.
Briefly, DNA was first separated from four pairs of
matched fresh-frozen maternal peripheral blood and pla-
cental tissue samples using the standard phenol/chloro-
form technique. Then 2μg of the genomic DNA samples
were sheared into 200–1000 bp fragments by Mse I (5′-
TTAA) and purified to remove any fragments smaller
than 100 bp using a MicroDNA Purification Kit (CoWin
Biotech Company, Beijing, China) following the manu-
facturer’s instruction. Afterwards, the purified DNA frag-
ments were used to enrich methylated DNA using a
Table 1 Primer pairs used for direct bisulfite sequencing





PITX2 NM_000325.5 F TAGTGATAGGCGTTTCGGGTT
R CCACTACATACTAACAAACACTCAAAT
TLX3 NM_021025 F TCGGTTGAGGATTAGAGGGATT
R AACGCCACCTAACCATCTATTC
OTX2 NM_172337.1 F AGTTGTGTTAGGTTGAGGGAG
R AATCCCAAAAACCTTTTTAAA
MNX1 NM_001165255 F TTTAAGAAATAGCGAGAGGGAG
R AAACGCTCGTAACATAATCCC
NR2F2 NM_001145155 F CGTATCGTGGATTTGGAGTAGGGTATT
R AACAAACTCGCTAACAAATAAACRACATT
TFAP2C NM_003222 F CGAAGTGTTAGGGTTTTGTGTGT
R CGACCTTAAACAACAACCAAATCC
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the manufacturer’s protocol. The MIRA-captured DNA
segments were purified and amplified using GenomePlex
Whole Genome Amplification Kit (Sigma) as per the
supplier’s instruction. The products of whole genome
amplification from the total input DNA without MBD
enrichment and methylation-enriched DNA from each
of the samples were labeled with cy3-dCTP and cy5-
dCTP respectively, using Klenow enzyme (Takara,
Dalian, China). The fluorescent dye labeled DNA was
mixed and hybridized to Agilent human CpG island
microarrays that were designed to interrogate 61,982
CpG dinucleotides covering 4,162 genes. After
hybridization, the slides were washed and scanned on
the Agilent microarray platform according to Agilent’s
standard protocol. The data were extracted using Agilent
Feature Extraction software. Following global mean
normalization, faint probes with intensity <400 were
discarded and excluded from the analysis. Unsupervised
clustering analysis was performed using the Cluster soft-
ware. Probes were considered positive for differential
methylation between maternal blood and placental tissue
if the fold changes in their MIRA/Input signaling ratios
between the placental tissue and the maternal blood
were >1.2 or <0.83 (q <0.05) using SAM (significance
analysis of microarrays) [18]. The significant enrichment
of the Gene Ontology (GO) terms associated with the
hypermethylated genes was analyzed using the hypergeo-
metric distribution in the R language software package.
All microarray data have been submitted to the Gene
Expression Omnibus [GEO: GSE35997].
Validation of hypermethylated genes using direct
bisulfite sequencing
Of the top 15 hypermethylated genes identified by the
methylation microarray analysis, two significantly hyper-
methylated genes (NR2F2 and TFAP2C) were selected
for further validation in independent samples using dir-
ect bisulfite sequencing. Briefly, genomic DNA was
bisulfite converted using the DNA methylation detection
kit (BioChain, Hayward, CA, USA) as per manufacturer’s
protocol. Then, 125 ng of bisulfite converted DNA was
PCR amplified in 50 μL reaction mixture containing
1 × PCR Buffer (Mg2+ Plus), 200 μM of each dNTP,
0.5 μM of forward and reverse primers (primer
sequences are provided in Table 1) and 1.25 units of
TaKaRa Taq HS. The PCR cycling conditions were: 94°C
for 5 min; 45 × (94°C for 30 s, 55°C for 30 s, 72°C for
30 s); 72°C for 7 min, and 4°C hold. The PCR products
were cleaned using a MicroDNA Purification Kit. The
purified PCR products were then subjected to direct se-
quencing in an ABI 3500xL Genetic Analyzer using the
same forward primers that were used for the PCR ampli-
fication (Table 1).Validation of hypermethylated genes using COBRA
COBRA was used to validate the methylation status of
four of the genes (PITX2, TLX3, OTX2 and MNX1) from
among the top 15 hypermethylated genes [19]. The
principle of the COBRA method is that the cytosine in
DNA is converted to uracil by bisulfite treatment while
methylated cytosine is retained as cytosine. Thus, methy-
lated and unmethylated cytosines can be distinguished
by digesting the DNA with a restriction enzyme that
recognizes sequences containing CpG. For the COBRA
assays, the bisulfite conversion, PCR amplification and
purification were carried out as described above. The
primer sequences used for the COBRA validation are
listed in Table 1. The purified PCR products were
digested with the BstU I (CG#CG) restriction enzyme
(New England Biolabs, Ipswich, MA, US) and then elec-
trophoresed on 2% agarose gels supplemented with eth-
idium bromide for visualization under a UV light.Results
MIRA microarray analysis of DNA methylation
To screen hypermethylated genes in fetal tissue relative
to those in maternal circulation, we used an MIRA ap-
proach to identify significantly hypermethylated genes in
four placental tissue samples and the four corresponding
maternal peripheral blood samples. First, we performed
an unsupervised clustering analysis on 9382 probes with
intensities that were greater than 400 in at least one of
the samples. This analysis showed that there was distinct
clustering of the maternal peripheral blood and placental
tissue samples (Figure 1), suggesting that there were ob-
vious differences of methylation between the maternal
peripheral blood and the placental tissue.
Figure 1 Unsupervised clustering in four pairs of matched
placental tissue and maternal peripheral blood samples.
Yin et al. BMC Medical Genomics 2012, 5:26 Page 4 of 8
http://www.biomedcentral.com/1755-8794/5/26The methylation difference, represented by copy num-
ber difference of MBD protein enriched DNA in MIRA
approach, is similar to the DNA copy number difference
in array-based comparative genomic hybridization
(aCGH) and is quite different from the gene expression
for one copy of DNA expresses various copies of mRNA.
In the well-established aCGH method, the cutoff for
detecting DNA copy differences is usually set to be
>1.25 of probe ratio value [20,21]. This cutoff is lower
than the one used in mRNA expression profiling analysis
where the alteration ratio is usually set to be >2.0. In
the present study, SAM analysis was performed basedon the cutoff criteria that fold changes in MIRA/Input
signaling ratios between placental tissues versus mater-
nal bloods were >1.2 or <0.83 (q <0.05). We detected
3,774 positive probes corresponding to 783 differentially
methylated genes; of these, 310 genes had at least two
positive probes with fold changes in the MIRA/Input
signaling ratios between placental tissues and maternal
bloods that were above 1.2 (q <0.05). The 310 genes
were selected as hypermethylated genes (Additional file 1:
Table S1). The top 15 hypermethylated genes had more
than ten positive probes and are listed in Table 2.
The significant enrichment analysis of the GO terms
for the differentially methylated genes demonstrated that
the 783 differentially methylated genes were involved in
many important biological processes such as regulation
of transcription and organismal development (Figure 2).
Validation of hypermethylated genes using direct
bisulfite sequencing
Bisulfite sequencing allows the methylation analysis of
the cytosine residues in a given sequence. Two protocols
have been employed for bisulfite sequencing: cloning-
based sequencing and direct PCR sequencing. Cloning-
based sequencing is very useful in determining the
pattern of mosaic methylation of individual molecules.
However, it is labor-intensive and time-consuming be-
cause it requires the cloning of the PCR product before
sequencing and usually the sequences of at least ten
individual clones are required to provide an accurate
estimate of methylation in the population of molecules.
Direct PCR sequencing only provides the averaged
methylation status in a population of molecules but this
method is convenient for the rapid assessment of global
methylation levels in a population of molecules. In this
study, direct bisulfite sequencing was performed to val-
idate the reliability of the methylation microarray ana-
lysis. Two genes, TFAP2C and NR2F2, from the top 15
hypermethylated genes identified by MIRA analysis were
selected for methylation validation in maternal periph-
eral blood, placental tissue and chorionic villus samples.
The sequencing results indicated that TFAP2C and
NR2F2 were hypomethylated at multiple CpGs sites in
maternal peripheral blood samples and hypermethylated
at multiple CpGs sites in the placental tissue and chori-
onic villus samples (Figure 3) of fetal origin.
Validation of hypermethylated genes using COBRA
COBRA is a sensitive and convenient assay to measure
DNA methylation status at specific gene loci in small
amounts of genomic DNA [22,23]. COBRA has been
widely used for confirming methylation results obtained
by microarray analysis [12,24]. Here the COBRA assay
was used to validate the reliability of the methylation
microarray analysis and to screen for fetal methylation





Positionb Gene description Phenotype MIM Accession No.c
PITX2 27 3.19 I and D Paired-like homeodomain 2 180500, 137600, 604229, 180550
PAX6 20 2.34 P and I Paired box 6 106210, 604219, 120430, 120200,
136520, 206700, 148190, 165550, 604229
NR2F2 17 3.22 P, I and D Nuclear receptor subfamily 2, group F, member 2
MNX1 15 2.50 P, I and D Motor neuron and pancreas homeobox 1 176450
TLX3 15 3.69 P and D T-cell leukemia homeobox 3
PAX9 15 2.33 P and I Paired box 9 604625
SALL1 15 2.27 P, I and D Sal-like 1 (Drosophila) 107480
MAD1L1 14 3.18 I MAD1 mitotic arrest deficient-like 1 (yeast) 176807
TBX3 14 4.50 P, I and D T-box 3 181450
HLX 14 2.01 P, I and D H2.0-like homeobox
PDX1 13 2.88 P, I and D Pancreatic and duodenal homeobox 1 606392, 260370, 125853
TFAP2C 13 4.78 P Transcription factor AP-2 gamma
SIX1 12 3.13 P, I and D SIX homeobox 1 608389, 605192
SIM1 12 2.98 P and I Single-minded homolog 1 (Drosophila) 601665
OTX2 12 3.39 P and D Orthodenticle homeobox 2 610125, 613986
Several probes for each gene are present on the microarray. aThe average ratio of the probe density of the positive probe in placental tissue to that in the
maternal peripheral blood calculated using the SAM software. bThe letters in this column refer to different regions of the gene: P, promoter; I, inside; D,
downstream. cThe phenotype MIM Accession Number is from the OMIM database (www.ncbi.nlm.nih.gov/omim).
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lated genes were selected for validation in four pairs of
matched placental tissue and maternal peripheral blood
samples. The results in Figure 3 show that PITX2, TLX3,
OTX2 and MNX1 were all methylated in placental tis-
sues but not in maternal peripheral bloods. Because the
placental tissues are at a late stage of fetus development,
we also measured the methylation status of these four
genes in ten amniotic fluid and five chorionic villus sam-
ples using a COBRA assay to assess the methylation sta-
tus at the early and middle stages of fetus development.
The results showed that PITX2, TLX3, OTX2 and MNX1
were also methylated in all the chorionic villus samples
tested (Figure 4), but were not methylated in the major-
ity of the tested amniotic fluid samples.
Discussion
The MIRA microarray does not require restriction endo-
nuclease, antibody or bisulfite treatment of the genomic
DNA and, therefore, offers many advantages over exist-
ing methods for the genome-wide screening of DNA
methylation. MIRA microarrays have been used to iden-
tify candidate methylation biomarker for cancer diagno-
sis [12,25]. In this study, we applied this approach to
seek candidate biomarkers for noninvasive prenatal diag-
nosis. Currently, noninvasive prenatal screening typically
involves a combination of ultrasound tests and the
measurement of non-specific maternal serum markers.
These screening tests are limited to trisomies ofchromosomes 21 and 18 and do not reliably diagnose or
exclude these types of abnormalities. The discovery of
fetal DNA in maternal plasma opened new doors for
non-invasive prenatal diagnosis. However, the presence
of background maternal DNA interferes with the ana-
lysis of fetal DNA which usually constitutes less than
10% of the total circulating free DNA in early pregnancy
[26]. This has posed significant technical hurdles for the
detection of fetal genetic loci that are not completely ab-
sent from the maternal genome using current PCR-
based approaches [27]. To overcome this problem, the
differential methylation between placentally and mater-
nally derived cell-free DNA sequences has been investi-
gated [28]. Many studies have shown that these
epigenetic differences may serve as potential fetal mo-
lecular markers for noninvasive prenatal diagnosis [7,8].
However, only a limited number of genomic regions
have been identified or tested so far and the majority of
studies have focused only on fetal chromosomal aneu-
ploidy detection, for example, of chromosomes 21 and
18. Here, we aimed to identify methylation biomarkers
for the prenatal diagnosis of not only fetal chromosomal
aneuploidies but also of monogenic diseases at a
genome-wide level.
Promoter methylation plays important roles in regulat-
ing gene expression both in development and in human
disease and, so far, DNA methylation studies have
mainly been focused on the promoter regions of genes.
Recently, methylation of the gene body (sometimes
Figure 2 Gene ontology categories enriched in differentially methylated genes between placental tissues and maternal peripheral
blood.
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a role in transcriptional regulation and efficiency [29]
and intragenic methylation is attracting increasing atten-
tion. Therefore, in this study, we investigated the hyper-
methylation of genes based on the methylation status of
both the promoter and the gene body.
Large differences were observed in methylation pat-
terns between maternal peripheral blood and placental
tissue. Further analysis based on GO terms revealed that
many of the differentially methylated genes were
involved in regulation of transcription and multicellular
organismal. This result might suggest that the differen-
tially methylated genes contribute to the control of gene
expression during embryonic development. It is well
known that DNA methylation changes during embryonic
development are frequent events that play major roles inFigure 3 CpG methylations of TFAP2C and NR2F2 measured using dir
nucleotide positions −1516(38), −1475(79), −1471(83) and −1464(87) in TFA
indicates either T or C.regulating gene expression and other developmental
processes. It is worth noting that differentially methy-
lated genes were involved in mammary gland develop-
ment (Figure 2). This finding suggested that methylation
may play major roles in regulating lactation.
The bisulfite sequencing and COBRA assays both con-
firmed that the observed genes were hypermethylated in
placental tissue and chorionic villus; however, the DNA
methylation was unobvious in the amniotic fluid sam-
ples. The placental tissue samples, obtained immediately
after delivery, are from a late-stage placenta and the
chorionic villus tissue samples are from an early-stage
placenta, the amniotic fluid is not a placental tissue. The
cells in amniotic fluid are an admixture of various cells
from various fetal tissues, mainly fibroblasts, epithelial
cells and amniocytes that are shed from the fetusect bisulfite sequencing. Methylated CpGs were observed at
P2C, and at −2467(44), −2446(65), −2439(72) and −2418(93) in NR2F2. Y
Figure 4 Methylations of PITX2, TLX3, OTX2 and MNX1 genes validated using the combined bisulfite restriction analysis. Bisulfite
converted genomic DNA was amplified with gene-specific primers followed by digestion with a methylation sensitive enzyme BstUI (CG#CG).
Methylation status was measured in placental tissue (P), maternal peripheral blood (M) and chorionic villus (C). The expected enzyme-digested
pattern of the PCR products in which CpG islands were fully methylated was depicted on right side.
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methylation differences in these samples may reflect tis-
sue specificity rather than developmental specificity.
Previous studies have shown that the circulating fetal
DNA in maternal peripheral blood are mainly from the
placenta [30] because the placenta is the only channel
for nutrient transport between mother and fetus. The
DNA in different tissues carries the same sequence in-
formation, no matter whether the sequences are methy-
lated or not. Therefore, the detection of fetal methylated
DNAs in maternal peripheral blood will yield fetal infor-
mation about genetic variations that may be useful for
the diagnosis of fetal genetic diseases. Furthermore, it is
convenient and feasible to discriminate between fetal
methylated DNA and maternal nonmethylated DNA in
maternal peripheral blood based on differences in their
methylation patterns. Thus, the observed methylation
differences of disease-associated genes between placental
tissue and maternal peripheral blood provide a founda-
tion for developing novel methods for the detection of
fetal genes in maternal peripheral blood.
We identified a large number of hypermethylated
genes in fetal tissues; most of these genes have been
recorded in the Online Mendelian Inheritance in Man
(OMIM) database (www.ncbi.nlm.nih.gov/omim) where
the relationship between abnormalities in these genes
and diseases has been defined. For example, mutations
in PITX2, a homeobox gene, are known to contribute to
Axenfeld-Rieger syndrome (ARS), an autosomal-
dominant developmental disorder [31,32]. The hyper-
methylated genes have great potential to be developed
into molecular markers for noninvasive prenatal diagno-
sis of monogenic disorders. In a future study, we will use
the MBD protein to enrich fetal hypermethylated DNA
fragments in maternal peripheral blood and furtherexplore the feasibility of using these hypermethylated
genes as biomarkers for noninvasive prenatal diagnosis
in large samples.
Conclusions
In this study we identified a lot of hypermethylated
genes and methylation sites in fetal tissues. Some of the
hypermethylated genes have great potential to be devel-
oped into molecular markers for noninvasive prenatal
diagnosis of monogenic disorders. Further clinical stud-
ies are warranted to confirm these findings.
Additional file
Additional file 1: Table S1. List of the hypermethylated genes in
placental tissue identified by MIRA based microarray.
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